

1. [FDA enhances warnings on group of strong antibiotics](#) – Reuters

The U.S. Food and Drug Administration has enhanced warnings of side effects of a group of strong antibiotics used to treat a variety of respiratory and urinary tract infections and limited their use to patients with no alternatives. The antibiotics known as fluoroquinolones include Johnson & Johnson's Levaquin, Bayer's Cipro extended-release tablets and Merck Inc's Avelox. The FDA added a box warning to the antibiotics in July 2008 to inform users about the increased risk of tendinitis in which the tissue connecting muscle to bone becomes inflamed.

2. [Lilly sales beat estimates, helped by newer drugs](#) – Reuters

Eli Lilly and Co on Tuesday reported better-than-expected quarterly sales, fueled by newer drugs, and predicted average annual revenue growth of at least 5 percent through the end of the decade due to its growing roster of medicines. The Indianapolis drugmaker, whose earnings growth resumed last year after three years of tumbling sales caused by competition from generic drugs, said investors can count on annual dividend increases in 2016 and beyond.

3. [Pharma sector receives Rs 4,975-crore FDI in FY16: Government](#) – The Economic Times

The drugs and pharmaceuticals sector has received foreign direct investment (FDI) of Rs 4,975 crore in 2015-16, parliament was informed today. "In the year 2014-15, FDI equity inflow of Rs 9,052 crore and in the year 2015-16, inflow of Rs 4,975 crore have been received in the drugs and pharmaceutical sector," Minister of State for Chemicals and Fertilizers Mansukh L Mandaviya said in a reply to Lok Sabha. FDI policy provides for 100 per cent FDI under automatic route in greenfield pharma and upto 100 per cent under government route in brownfield pharma, he added

4. [US' Gilead faces competition from Bangladesh's Beacon pharma](#) – The Economic Times

In a classic David Vs Goliath case, the US-based drugmaker Gilead that has made billions of dollars over its blockbuster range of Hepatitis C drugs is facing an unconventional challenger. Beacon Pharma, a little known Bangladeshi drugmaker, has emerged as the David to the Goliath that Gilead is. Beacon has become the first generic drug company in the world to produce copycat versions of Gilead's newly launched Epclusa (Sofosbuvir + Velpatasvir) — a drug used to treat all types of Hepatitis C infections. One of the revolutionary drugs, Epclusa has a cure rate of 95 per cent, but with a tag of \$75,000 it is considered out of reach to even the wealthy.

1. [FDA enhances warnings on group of strong antibiotics](#) – Reuters
2. [Lilly sales beat estimates, helped by newer drugs](#) – Reuters
3. [Pharma sector receives Rs 4,975-crore FDI in FY16: Government](#) – The Economic Times
4. [US' Gilead faces competition from Bangladesh's Beacon pharma](#) – The Economic Times
5. [Lupin in talks with Japan's Astellas, Shionogi to buy their off-patent drug brands](#) – The Economic Times
6. [If IPR owner is abroad, its transfer cannot be taxed in India: Delhi HC](#) – Mint
7. [Fosun set for \\$1.4bn Gland Pharma deal](#) – The Times of India
8. [Pharma firms turn to foreign lands for manufacturing](#) – Hindustan Times
9. [AbbVie, Bristol-Myers collaborate to evaluate combo of Rova-T plus Opdivo & Opdivo + Yervoy regimen in relapsed extensive-stage SCLC](#) – Pharmabiz.com
10. [Poor Show by Pharma Cos](#) – Pharmabiz.com

5. [Lupin in talks with Japan's Astellas, Shionogi to buy their off-patent drug brands](#) – **The Economic Times**  
Lupin, India's third-largest drugmaker, is in talks with Japan's Astellas and Shionogi to buy the off-patent medicine brands they have separately put on the block, two people aware of the development said. The basket of drugs that Astellas and Shionogi are divesting could fetch each company about \$100 million, the two senior industry executives cited earlier said, adding that for Lupin, their acquisition will result in a wider offering in the Japanese market where its sales last fiscal stood at Rs 1,364 crore, or 10 per cent of its global revenue.
6. [If IPR owner is abroad, its transfer cannot be taxed in India: Delhi HC](#) – **Mint**  
In a significant decision, the Delhi high court on Monday ruled that transfer of intangible assets like intellectual property whose owners were not based in India could not be taxed in the country. In what would benefit Foster's Australia, the petitioner (now known as CUB Pty), the high court overturned a decision of the Authority of Advance ruling which said that such transfer would mean that income accrued in India. "The situs of the owner of an intangible asset would be the closest approximation of the situs of an intangible asset. This is an internationally accepted rule, unless it is altered by local legislation," the court noted in its ruling.
7. [Fosun set for \\$1.4bn Gland Pharma deal](#) – **The Times of India**  
Chinese billionaire Guo Guangchang, who runs a diversified conglomerate under the banner Fosun International, is set to make a \$1.4-billion acquisition of KKR-backed Gland Pharma, a contract manufacturer of injectables, later this week. The 49-year-old Guangchang's Shanghai Fosun Pharmaceutical (Group) Co and Hyderabad-based Gland Pharma are expected sign the deal in Singapore on Wednesday evening and announce it to the Hong Kong stock exchange by Thursday morning, people directly familiar with the matter said. Besides being the largest Chinese M&A, the deal would also see one of that country's wealthiest investing into the Indian manufacturing story, giving heft to Prime Minister Narendra Modi's 'Make in India' initiative. Gland manufactures injectables to companies in India and the US like Mylan and Dr Reddy's. Promoter Ravi Penmetsa's family and KKR own over 95% stake in the company.
8. [Pharma firms turn to foreign lands for manufacturing](#) – **Hindustan Times**  
In a move that can go against Prime Minister Narendra Modi's much-hyped 'Make in India' initiative, domestic drugmakers are hunting for manufacturing hubs on the foreign lands citing regulatory delays, increased cost of land, and spiking cost of unskilled labour in the country. While pharmaceutical companies such as Biocon, Lupin and Glenmark have manufacturing units outside India, IPCA Laboratories is looking for land in Abu Dhabi, Dubai, analysts said. Earlier this year, Cipla closed a \$550-million deal for its first US-based manufacturing facility.
9. [AbbVie, Bristol-Myers collaborate to evaluate combo of Rova-T plus Opdivo & Opdivo + Yervoy regimen in relapsed extensive-stage SCLC](#) – **Pharmabiz.com**  
AbbVie and Bristol-Myers Squibb Company announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie's investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituzumab tesirine) in combination with Bristol-Myers Squibb's Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a treatment for relapsed extensive-stage small cell lung cancer (SCLC). The phase 1/2 clinical programme will explore the potential of combining Bristol-Myers Squibb's immuno-oncology agents, which are designed to alleviate immune suppression, in conjunction with AbbVie's investigational antibody drug conjugate, Rova-T, to drive improved and sustained efficacy and tolerability above the current standard of care. Rova-T is a novel antibody drug conjugate that targets and eliminates tumor initiating cells and other bulk tumor cells. This collaboration will determine if the targeted cell killing and antigen release caused by Rova-T may further enhance the effect of immunotherapy.
10. [Poor Show by Pharma Cos](#) – **Pharmabiz.com**  
The Pharmabiz study of the performances of India's top 100 listed pharmaceutical companies during 2015-16 brings out a complex profile of this key industry of the country. The net sales of these 100 companies increased by 10.3 per cent to Rs. 190,627 crore during 2015-16 from Rs.

172,842 crore in the previous year. That is certainly a good sales growth rate considering the hard times several industries are going through for some time now. Among the 100 companies, 30 recorded net sales of over Rs. 1,000 crore during 2015-16 contributing to 88 per cent of the aggregate net sales. The net sales of these 30 companies increased by 11.9 per cent to Rs. 167,152 crore during 2015-16 from Rs. 149,430 crore in the previous year. Among all the pharmaceutical companies, Sun Pharma stands out at the number one position with a net sales of Rs. 27,744 crore in 2015-16 as against Rs. 27,245 crore after merger of Ranbaxy Laboratories in the previous year. Dr Reddy's Laboratories kept its No 2 position with net sales of Rs. 15,471 crore and Lupin stands at the third spot with net sales of Rs. 13,702 crore. The sales of these three top companies, however, improved only by single digit at 1.8 per cent, 4.4 per cent and 8.7 per cent respectively during 2015-16.